Modest benefit to cognitive function with Avonex. (News).
A recent analysis of these trial results shows that people who received Avonex did better on some cognitive functions commonly affected by MS.
Participants in the Avonex trial had been given neuropsychological tests at the beginning and end of a 2-year period. The group taking a placebo (or inert injection) showed little or no change. The group taking Avonex showed modest improvement on tests that measured speed of information processing, recent memory, and other functions. These fundings were published in the December 2000 issue of the Annals of Neurology.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Product/Service Evaluation|
|Date:||Mar 22, 2001|
|Previous Article:||Researchers successfully measure cognitive fatigue in people with MS. (News).|
|Next Article:||Champion chapters rise to a challenge. (National MS Society News).|